APA (7th ed.) Citation

MJ, K., J, J., W, J., CM, C., SJ, K., HJ, C., . . . JC, L. (2026). Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: A prospective multicenter cohort study. Translational lung cancer research, 15(1), 13. https://doi.org/10.21037/tlcr-2025-aw-1216

Chicago Style (17th ed.) Citation

MJ, Kim, et al. "Clinical Implications of Plasma EGFR T790M and CtDNA Shedding Across Metastatic Sites in Plasma- or Tissue-confirmed EGFR-mutant Non-small Cell Lung Cancer Treated with Lazertinib: A Prospective Multicenter Cohort Study." Translational Lung Cancer Research 15, no. 1 (2026): 13. https://doi.org/10.21037/tlcr-2025-aw-1216.

MLA (9th ed.) Citation

MJ, Kim, et al. "Clinical Implications of Plasma EGFR T790M and CtDNA Shedding Across Metastatic Sites in Plasma- or Tissue-confirmed EGFR-mutant Non-small Cell Lung Cancer Treated with Lazertinib: A Prospective Multicenter Cohort Study." Translational Lung Cancer Research, vol. 15, no. 1, 2026, p. 13, https://doi.org/10.21037/tlcr-2025-aw-1216.